Adam R. Craig
Executive ChairDr. Adam R. Craig M.D., Ph.D., M.B.A., has been a Member of Clinical Advisory Board of Syntara Limited since September 2025. He has been a Director of eGenesis, Inc. since August 2025. He is Executive Chair of X4 Pharmaceuticals, Inc. from August 12, 2025. Dr. Craig has been the Chief Executive Officer and President of CTI BioPharma Corp. since March 20, 2017 and serves its Interim Chief Medical Officer. Dr. Craig was Director of CTI BioPharma Corp. from March 20, 2017 to June 26, 2023. Dr. Craig served as Independent Consultant at CTI BioPharma Corp. since 2016 until March 20, 2017. Dr. Craig served as an Interim Chief Medical Officer at Immune Design Corp. since June 2016 until April 26, 2017. He has years of experience in hematology, oncology and drug development in both the US and Europe. He is Executive Chairman of X4 Pharmaceuticals and was interim CEO of Stratus Therapeutics (formerly Garuda Therapeutics). He served as the Chief Medical Officer and Executive Vice President of Development at Sunesis Pharmaceuticals Inc. from March 1, 2012 to 2016. He oversaw the ongoing pivotal Phase 3 VALOR trial of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia (AML) and direct Sunesis’ global development program. He served as the Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd. from 2008 to 2012. He served as the Chief Medical Officer and Vice President of CytRx Oncology Corporation (formerly Innovive Pharmaceuticals, Inc.) from April 2005 to September 30, 2007. From December 17, 2003 to April 2005, he served as Vice President of Clinical Development and Medical Director of ArQule Inc. Dr. Craig joined ArQule from Ilex Oncology, Inc., where he was Senior Director of Clinical Development and Medical Director from April 2002 to December 2003. Prior to Ilex, Dr. Craig served as Medical Adviser in oncology at Antisoma, from March 2001 to March 2002. He served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas. Dr. Craig was a Medical Research Council Clinical Research Fellow from January 1998 to February 2001. Dr. Craig is a Member of the Royal College of Physicians (UK) and undertook Post-Graduate Training in Pediatrics and Pediatric Oncology. Dr. Craig earned his Bachelor’s and Medical degrees from University of London’s Charing Cross and Westminster Medical School in July 1999 and holds a Ph.D. in Molecular Oncology from Leeds University in the U.K. in June 2001 and an MBA from the Open Business School, in the United Kingdom.
Positions
- Company NameX4 Pharmaceuticals, Inc.Stock CodeXFORPositionExecutive ChairColleagues
- JPJohn P. VolponePresident & COO
- DHDavid H. KirskeCFO, Treasurer & Corporate Secretary
- RPRichard PetersFounder
- RTRenato T. SkerljFounder
- KTKeith T. FlahertyFounder & Member of Corporate Advisory Board
- MSMichael Stephen WyzgaLead Independent Director
- MWMurray W. StewartDirector
- MJMichael J. VasconcellesMember of Corporate Advisory Board
